1. Home
  2. LEXX vs SHFS Comparison

LEXX vs SHFS Comparison

Compare LEXX & SHFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • SHFS
  • Stock Information
  • Founded
  • LEXX 2004
  • SHFS 2015
  • Country
  • LEXX Canada
  • SHFS United States
  • Employees
  • LEXX N/A
  • SHFS N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • SHFS Finance: Consumer Services
  • Sector
  • LEXX Health Care
  • SHFS Finance
  • Exchange
  • LEXX Nasdaq
  • SHFS Nasdaq
  • Market Cap
  • LEXX 25.8M
  • SHFS 20.8M
  • IPO Year
  • LEXX N/A
  • SHFS N/A
  • Fundamental
  • Price
  • LEXX $1.45
  • SHFS $0.32
  • Analyst Decision
  • LEXX Strong Buy
  • SHFS
  • Analyst Count
  • LEXX 1
  • SHFS 0
  • Target Price
  • LEXX $7.00
  • SHFS N/A
  • AVG Volume (30 Days)
  • LEXX 128.9K
  • SHFS 127.0K
  • Earning Date
  • LEXX 04-08-2025
  • SHFS 03-31-2025
  • Dividend Yield
  • LEXX N/A
  • SHFS N/A
  • EPS Growth
  • LEXX N/A
  • SHFS N/A
  • EPS
  • LEXX N/A
  • SHFS 0.10
  • Revenue
  • LEXX $496,923.00
  • SHFS $15,658,629.00
  • Revenue This Year
  • LEXX $30.72
  • SHFS N/A
  • Revenue Next Year
  • LEXX $31.85
  • SHFS N/A
  • P/E Ratio
  • LEXX N/A
  • SHFS $3.19
  • Revenue Growth
  • LEXX 77.63
  • SHFS 7.78
  • 52 Week Low
  • LEXX $1.15
  • SHFS $0.30
  • 52 Week High
  • LEXX $6.85
  • SHFS $1.01
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 43.81
  • SHFS 38.40
  • Support Level
  • LEXX $1.15
  • SHFS $0.30
  • Resistance Level
  • LEXX $1.44
  • SHFS $0.38
  • Average True Range (ATR)
  • LEXX 0.14
  • SHFS 0.03
  • MACD
  • LEXX 0.01
  • SHFS -0.00
  • Stochastic Oscillator
  • LEXX 58.82
  • SHFS 24.30

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About SHFS SHF Holdings Inc.

SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring among others.

Share on Social Networks: